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Abstract 
 
There is a growing interest in using a longitudinal observational databases to detect drug safety 
signal. In this paper we present a novel method, which we used online during the OMOP Cup. 
We consider homogeneous ensembling, which is based on random re-sampling (known, also, as 
bagging) as a main innovation compared to the previous publications in the related field. This 
study is based on a very large simulated database of the 10 million patients records, which was 
created by the Observational Medical Outcomes Partnership (OMOP). Compared to the 
traditional classification problem, the given data are unlabelled. The objective of this study is to 
discover hidden associations between drugs and conditions. The main idea of the approach, which 
we used during the OMOP Cup is to compare the numbers of observed and expected patterns. 
This comparison may be organised in several different ways, and the outcomes (base learners) 
may be quite different as well. It is proposed to construct the final decision function as an 
ensemble of the base learners. Our method was recognised formally by the Organisers of the 
OMOP Cup as a top performing method for the Challenge N2. 
 
Keywords: longitudinal observational data, signal detection, temporal pattern discovery, 
unsupervised learning, electronic health records 
 
INTRODUCTION 
 
An improvement of drug safety and the identification of adverse drug events remains a 
very important problem. Several recent drug safety events have highlighted the need for new data 
sources and algorithms to assist in identifying adverse drug events in a more timely, effective, 
and efficient manner. The methods and statistical tools used on large healthcare data sources (e.g., 
administrative claims and electronic health records) have been lacking and are not yet 
systematized to look at disparate databases. The Observational Medical Outcomes Partnership 
(OMOP) conducted a Cup Competition as a catalyst for new methods development to identify 
relationships in data between drugs and adverse events or conditions (OMOP Newsletter, 2010). 
 
To provide an objective basis for monitoring and assessing the safety of marketed 
products, pharmaceutical companies and regulatory agencies have implemented post-marketing 
surveillance activities based in large measure on the collection of spontaneously generated 
adverse reaction reports. Report initiation (by health professionals and consumers) is generally 
voluntary; by contrast, the pharmaceutical companies are generally under legal obligation to 
follow up on reports that they receive and to pass them along to various regulatory authorities 
(Fram et al., 2003). 
 
Every drug has undergone extensive testing before being released to the market, but even 
pre-marketing clinical trials involving thousands of people cannot uncover all adverse events that 
may occur in a much larger and diverse population. Traditionally, post-marketing safety signal 
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detection has relied on voluntary, spontaneous reporting of suspected adverse drug reactions by 
health care professionals, patients, and consumers (Schuemie, 2010). There is a global interest in 
using electronic health records for active drug safety surveillance. Many methods have been 
developed and exploited for quantitative signal detection in spontaneous reporting databases, 
most of these are based on disproportionality methods of case reports.  
 
A full safety profile of a new drug can never be known at the time that it is introduced to 
the general public. Whereas premarketing clinical trials do consider safety endpoints, they are 
limited in the types and numbers of patients exposed. Actual clinical practice often differs from 
the controlled setting of a clinical trial, with respect to the indication for treatment, concomitant 
medication, and dosage at which a drug is prescribed. Also, it may differ over time. As a 
consequence, safety monitoring and evaluation must continue throughout a drug’s life-cycle 
(Norén et al., 2009). 
 
In this paper we would like to share our successful experience, which was obtained 
online during the OMOP 2010 Cup. Also, we would like to direct readers to some selected 
publications (Nikulin, 2008), (Nikulin and McLachlan, 2010) and (Nikulin et al., 2011), where 
we reported our successful models and methods, which were used during different data mining 
Challenges. 
 
OMOP CHALLENGE 
 
OMOP is a public-private partnership designed to improve the monitoring of drugs for 
safety and effectiveness. The partnership is conducting a two-year research initiative to determine 
whether it is feasible and useful to use automated healthcare data to identify and evaluate safety 
issues of drugs on the market. The Partnership’s methodological research is conducted across 
multiple disparate observational databases (administrative claims and electronic health records). 
The series of studies being conducted include assessing different types of automated healthcare 
data, developing tools and methods to analyze the databases, and evaluating how analyses can 
contribute to decision-making. 
 
OMOP relies on the expertise and resources of the U.S. Food and Drug Administration, 
other federal agencies, academic institutions, the pharmaceutical and health insurance industries 
and non-profit organizations. A network of institutions, managed by the Foundation for the 
National Institutes of Health, carries out specific OMOP tasks, and all together, more than 100 
partners are collaborating. Throughout the work phases of OMOP all work products are made 
publicly available to promote transparency and consistency in research. 
 
The competition started in September 2009. OMOP provided the participants with a large 
simulated data set resembling healthcare data that was “spiked” with adverse events. The 
competitors had to find the signals by generating methods to identify relationships in the data 
between drugs and medical outcomes (adverse events). The goal was to develop methods that 
correctly identified true drug-event associations while minimizing false positive findings. 
Methods were evaluated by how accurately they predicted the known relationships that existed in 
the data. At the end of the competition, which was closed on March 31, 2010, there were over 
sixty competitors from many fields and entities. 
 
OMOP database 
 
The given database includes records of 10 million patients with dates when observation 
was started and ended. The overall observation period is 10 years. For any particular patient we 
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have 2 sequences: 1) drugs with starting and ending dates; 2) conditions with starting date. The 
total numbers of drugs and conditions are 5,000 and 4,519, respectively. Accordingly, the total 
number of possible associations is 22,595,000. There are also some demographical information 
available, such as age and sex. We shall denote by D and C sets of all drugs and conditions. As an 
illustration, the organisers made available a small subset of pairs  {drug, condition} with true 
label (4000 positive and 3920 negative), but we did not use this information in the training 
process. 
 
More details regarding the database and the Challenge may be found on the OMOP web-
site*. Most of the pre-processings were conducted using special software written in Perl, the main 
algorithms were implemented in C. In addition, we used special codes written in Matlab. 
 
DISPROPORTIONALITY ANALYSIS (DPA) 
 
In studying the temporal association between two events, it is convenient to let one event 
set the relative time frame in which the incidence of the other event is examined. We shall in the 
context of this paper let drug prescriptions define the relative time frame in which the incidence 
of other medical events is examined. The other medical events considered include notes of 
clinical symptoms, signs, and diagnoses, and prescriptions of other drugs. Our objective is to 
identify interesting temporal patterns relating the occurrence of a medical event to first 
prescriptions of a specific drug (Norén et al., 2009).  
 
Let us denote by ∆  a threshold temporal parameter (for example it may be in the range 
of 30-60 days). Then, we can consider the observation period T (for example, it may be the whole 
period of 10 years). We shall consider all the listed patients and shall compute dcn  to be the 
numbers of associations/cases, where  
 
,0 ∆≤−≤ dc tt                                                                         (1) 
ct  and dt  are the dates when condition c and drug d were started. 
  
As a next step, we count dn  and cn  to be the numbers of the times drug d and condition 
c were found within the time interval T. Note that dn  and cn  were computed independently. 
 
Assuming that events are independent, the expected number of associations may be 
calculated according to the following formula 
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where f is a logarithmic or power function, α is a smoothing or shrinkage parameter. In our 
experiments we used .5.01.0 ≤≤ α  
 
Mean average precision 
 
The performance of the solutions was measured using the Mean Average Precision 
(MAP),  metric often used in the field of information retrieval. It measured how well a system 
ranks items, and emphasizes ranking true positive items higher. It is the average of precisions 
computed at the point of each of the true positives in the ranked list returned by the method 
(Schuemie, 2010). 
 
With the approach presented in this section we achieved result MAP = 0.12 for the 
Challenge 1. 
 
TEMPORAL ANALYSIS 
 
Most likely, the ratings (3) will be too rough if they are calculated according to the whole 
time-interval T of 10 years. Therefore, it is proposed to split the whole interval T into several 
consecutive subintervals: ,,...,1,)( miT i = and calculate ,,...,1,)( mir idc = accordingly. The most 
suitable value m = 10, which corresponds to the number of years within the whole observation 
period. As an outcome, we can produce solution for Challenge 2 using ratings .,...,1,)( mir idc =  
 
Challenge 2: identifying drug-condition associations as data accumulates over time 
 
Timely detection of drug-related adverse events as part of an active surveillance system 
would allow patients and health care providers to minimise potential risks and inform decision-
making authorities as quickly as possible. Challenge 2 seeks to evaluate a method’s performance 
in identifying true drug-condition associations and discerning from false association as data 
accumulates over time. 
 
It is important to mention that an association is defined as a drug that increases the 
likelihood of a condition occurring. A condition that is less likely to occur after receiving a drug, 
possibly, as an intentional result of a treatment, is not counted as an association. 
 
For the second challenge, it was necessary to examine the first 500 drugs more closely. 
As requested, submissions should contain one entry for each such drug-condition combination at 
the end of each of 10 calendar years, resulting in 10 times 500 times 4519 (22,595,000) total 
records. That means, the size of all possible combinations for Challenge 2 was exactly the same 
as for Challenge 1. 
 
We calculated solution for Challenge 2 according to the formula 
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and observed MAP = 0.13. Also, we considered )10(dcs  in application to Challenge 1 with MAP = 
0.14. Figure 1 illustrates behaviour of the 16 selected  (strongest relations) pairs {d, c}, which are 
presented in Table 1. 
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RANDOM RESAMPLING (BAGGING OR HOMOGENEOUS ENSEMBLING) 
 
Bagging predictors is a method for generating multiple versions of a predictor and using 
these to get an aggregated predictor. The aggregation averages over the versions when predicting 
a numerical outcome and does a plurality vote when predicting a class (Breiman, 1996). In this 
section we consider method of random resampling: it is supposed that using the hundreds of 
predictors (base learners), based on the randomly selected subsets of the whole training set, we 
shall reduce the random factors. According to the principles of homogeneous ensembling, the 
final predictor represents an average of the base predictors. As a reference, we mention random 
forests (Breiman, 2001) is a well-known example of successful homogeneous ensemble. 
However, the construction of random forests is based on another method, which is linked to the 
features but not to the samples. 
 
With the method of random resampling we were able to achieve a dramatic improvement 
in performance: MAP=0.21 for Challenge 1 and MAP=0.18 for Challenge 2. 
 
The ratings for Challenge 2 were calculated according to the following formula 
 
,10,...,1,)(1
1
)()(
== 
=
yearjs
k
z
k
j
year
dc
year
dc                                                          (5) 
where j is a sequential index of the randomly selected jΩ  subset of patients, and, by definition, it 
is assumed that computation of )()( js yeardc  was based on jΩ . 
 
Table 1: List of 16 strongest (according to our evaluation) relations between 
drugs and conditions, where ratings were computed according to (4). Column 
“Figure 1” indicates horizontal label of the window in Figure 1, where this 
time-series of the corresponding relationship is presented. 
 
N Figure 1 Drug Condition Rating 
1 a1 198 4017 6214.97 
2 a2 199 4018 6105.93 
3 a3 80 4011 5843.94 
4 a4 3 4002 5802.4 
5 b1 314 4025 5700.24 
6 b2 137 4013 5623.87 
7 b3 362 3509 5613.11 
8 b4 437 4039 5585.65 
9 c1 2 4002 5543.93 
10 c2 471 1996 5311.32 
11 c3 318 4027 5302.99 
12 c4 251 4020 5289.66 
13 d1 79 4011 5256.8 
14 d2 339 4032 5233.38 
15 d3 198 1280 5208.57 
16 d4 3 1377 5179.46 
 
Identifying relationships between drugs and medical conditions  6
Selection of the patients was conducted according to the condition: 65.0≤γ , where γ is 
a standard uniformly distributed random variable. Based on our experiments, the number of 
random samples k=100 is a quite sufficient. In addition, we decided to extend the random 
sampling further, and used as a threshold parameter ∆ in (1) uniformly distributed random 
variable: .6040 ≤∆≤  
 
 
Figure 1. Temporal dependences (ratings as a function of the years) for the selected pairs {drugs, 
conditions}, which are presented in Table 1. 
 
 
Note that we used solution )10(dcz  for Challenge 1. Figure 2(a) illustrates the 
structure/histogram of the solution )10(dcz , which was reduced to the logarithmic scale, where we 
used only drugs with indexes from 1 to 500 (this corresponds to Challenge 2). In accordance with 
Figure 2(a), an absolute majority of the pairs {d, c} has no expected relations. Figure 2(b) shows 
histogram of the right part of the solution presented in Figure 2(a) with some potential links. 
 
 
DPA: A SECOND APPROACH BASED ON THE DRUG ERAS 
 
Compared to the first approach of DPA, we shall use here not a counter of the number of 
times when drug was used, but the total duration in days when drug was used. 
 
Let us denote by dh  the total duration of the time when drug d was used during 
observational period T. Then, we can rewrite (2) in this way 
 
,cddc nb θ=                                                                                             (6) 
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Remark 1. Based on our experimental evaluations, there is a significant difference between 
formulas (2) and (6) in terms of the related outcomes. The formulas (2) and (6) are similar in the 
structural sense, and represent the most important initial steps.  The following steps to construct 
solution for this particular method are the same: we can apply (6) to (3). Then, we can repeat the 
temporal analysis (4) and resampling (5). As an outcome of this modified procedure we had 
observed the scores: MAP = 0.225 for Challenge 1 and MAP = 0.205 for Challenge 2. 
 
Figure 2. (a) histogram of the solution )10(dcz , which is defined in (5); (b) histogram of the right 
part of the solution )10(dcz (with potential links between drugs and conditions); (c) function w for 
the temporal weighting. 
 
 
HETEROGENEOUS ENSEMBLING 
 
Definition. An ensemble is defined as a heterogeneous if the base models in an ensemble are 
generated by methodologically different learning algorithms. On the other hand, an ensemble is 
defined as a homogeneous if the base models are of the same type (for example, resampling or 
bagging as discussed above).  
 
As far as solutions DPA1 and DPA2, which are based on expected numbers of 
associations (2) and (6), are very different in a structural sense, they cannot be linked together 
directly. At the same time we know that the qualities of both solutions DPA1 and DPA2 are high. 
The later observation represents a very positive factor, which indicates that the solutions DPA1 
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and DPA2 contains different information, which may lead to further improvement if linked in a 
proper way.  
 
Using an ensemble constructor (Nikulin and McLachlan, 2009), we can adjust one 
solution to the scale of another solution. After that,  we can compute an ensemble solution as a 
linear combination: 
,2)1(1 DPADPAENS ⋅−+⋅= ττ                                                                (7) 
where 1DPA  is the same as DPA1 solution, which was adjusted to the scale of DPA2 solution, 
10 << τ  is a positive weight coefficient. Clearly, the stronger performance of the solution DPA2 
compared to DPA1 the smaller will be value of the coefficient τ. 
 
With an ensemble constructor (7), we observed MAP=0.23 for Challenge 1 and 
MAP=0.22 for Challenge 2, where we used τ = 0.3. 
 
TEMPORAL WEIGHTING FOR COMPUTATION OF THE NUMBERS OF 
ASSOCIATIONS 
 
According to (3), the value of dcn  is a very important. Clearly, the strength of the signal 
depends essentially on the difference dc tt − , subject to the condition (1). Based on our statistical 
analysis (and, also, on some qualitative considerations), we decided to implement the following 
formula 
 
( ),
∆+≤≤
−=
dcd ttt
dcdc ttwn                                                                                 (8) 
where the structure of weight function w is illustrated in Figure 2(c): it is logical to assume that 
reaction of the patient’s organism to drug is not an immediate, and the likelihood of the possible 
association will decline over time after some point (6-10 days). 
 
COMPUTATION TIME 
 
A Linux multiprocessor computer with speed 3.2GHz, RAM 16GB, was used for the 
most of the computations. All the algorithms were implemented in C. The running time for 100 
random samplings according to (5) was about 10 hours.  
 
CONCLUDING REMARKS 
 
As a main outcome of our study, we can report very strong improvement with 
homogeneous ensembling (bagging). 
 
Also, we were trying to differentiate the matrices (5) for the particular age/sex groups, 
and then create submission assuming that the different age/sex groups are equally important. 
However, we did not observe any significant improvements with this approach. 
 
During the Challenge we conducted experiments with many different methods and 
approaches, which were not mentioned in the above Sections. For example, we tried 2D k-means 
clustering (Nikulin and McLachlan, 2009) and gradient-based matrix factorisation (Nikulin et al., 
2011) in application to the matrix (5) in order to smooth the noise, and can report some modest 
progress in this direction. 
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There may be several consecutive eras of one drug for the same patient. We achieved 
good improvements in the case if we use only first drug era, and ignore all the other eras. 
 
As to the prospective work: assuming that there are true relations for any drug/condition, 
it maybe a good idea to calibrate the matrix (5) so that the most “shiny” drugs/conditions will not 
outshine the other drugs/conditions. 
 
According to (Jelizarow et al., 2010), the superiority of new algorithms should always be 
demonstrated on an independent validation data. In this sense, an importance of the data mining 
contests is unquestionable. The rapid popularity growth of the data mining challenges 
demonstrates with confidence that it is the best-known way to evaluate different models and 
systems. 
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